Related Experiment Video
Updated: Aug 10, 2026
12:40
Cultivation of Heligmosomoides Polygyrus: An Immunomodulatory Nematode Parasite and its Secreted Products
Published on: April 6, 2015
Hypereosinophilic syndrome: an update
H Jeffrey Wilkins1, Martin M Crane, Kelly Copeland
1GlaxoSmithKline, King of Prussia, Pennsylvania 19406, USA. jeff.h.wilkins@gsk.com
American Journal of Hematology
|September 27, 2005
Summary
Hypereosinophilic syndrome (HES) is a rare, potentially fatal disorder. New targeted therapies like imatinib and mepolizumab show promise in treating HES by addressing specific disease pathways.
Area of Science:
- Hematology
- Immunology
- Rare Diseases
Background:
- Hypereosinophilic syndrome (HES) is a rare disorder characterized by persistent eosinophilia and organ dysfunction.
- Its pathophysiology involves cytokine dysregulation, particularly interleukin-5 (IL-5), impacting eosinophil maturation.
- HES can be fatal, especially myelodysplastic variants, necessitating effective treatments.
Purpose of the Study:
- To review current understanding and treatment strategies for Hypereosinophilic Syndrome (HES).
- To highlight the limitations of existing therapies and introduce novel targeted treatments.
- To explore the potential of new agents in improving outcomes for HES patients.
Main Methods:
- Literature review of Hypereosinophilic Syndrome (HES) pathophysiology and treatment.
- Analysis of historical and current therapeutic approaches, including corticosteroids and cytotoxic agents.
- Examination of emerging targeted therapies such as imatinib and mepolizumab.
Main Results:
- Current HES treatments have limitations in efficacy, tolerability, and long-term toxicity.
- Novel agents like imatinib (tyrosine kinase inhibitor) and mepolizumab (anti-IL-5 antibody) demonstrate clinical and hematological responses in HES.
- These targeted therapies may be effective in different patient subsets.
Conclusions:
- Targeted therapies offer potential for improved clinical outcomes in Hypereosinophilic Syndrome (HES).
- Further research into these agents can enhance understanding of HES pathophysiology.
- New treatments represent a significant advancement for this challenging condition.
More Related Videos
Related Concept Videos
01:22Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:29Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
01:24Nephrotic Syndrome I : Introduction
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...
01:26Nephrotic Syndrome II : Assessment and Medical Management
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
01:24Nephrotic Syndrome III : Nursing Management
Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...